Research & Development April 27, 2026 Sun Pharma to acquire Organon for $11.75bn By Salong Debbarma Organon, created through a spinoff from Merck & Co (MSD) in 2021, distributes more than 70 products across women’s health and general medicines, including biosimilars, reaching 140 countries.
Research & Development April 24, 2026 OZMOSI and Planview partner to enhance pharmaceutical data integration By Salong Debbarma The initiative aims to link external scientific data with internal R&D planning by creating a unified system that supports decision-making, improves market forecasting, and helps prioritise strategic investments.
Production & SalesResearch & Development April 24, 2026 Cumberland to sell drug portfolio to Apotex for $100m By Salong Debbarma Under the agreement, Apotex will acquire Cumberland’s branded medicines for cash, subject to approval by Cumberland’s shareholders. The partnership aims to establish a robust platform for speciality medicines
Research & Development April 23, 2026 Sanofi receives FDA approval for Tzield in paediatric diabetes By Salong Debbarma The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from
Research & Development April 23, 2026 MSD teams up with Google Cloud on agentic AI transformation By Salong Debbarma The collaboration aims to implement an agentic platform across MSD’s research and development (R&D), commercial, manufacturing and corporate divisions, with Google Cloud engineers working directly with MSD teams
Research & Development April 22, 2026 BioAegis and Prenosis partner for inflammatory disease therapies By Salong Debbarma The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis’ gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without suppressing immune
Research & Development April 22, 2026 Health Canada approves Biocon’s two denosumab biosimilars By Salong Debbarma The approval covers Bosaya in a 60mg/ml prefilled syringe and Vevzuo in a 120mg/1.7ml (70mg/ml) single-dose vial, both for subcutaneous injection. Denosumab therapies are used to increase bone
Research & Development April 21, 2026 Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy By Salong Debbarma The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. It could potentially broaden the approved use,
Research & Development April 21, 2026 Asahi Kasei acquires German company Aicuris By Salong Debbarma The move comes after Asahi Kasei signed a definitive agreement to acquire all issued shares of Aicuris for approximately €780m ($920.7m) earlier this year. The acquisition aligns with Asahi Kasei’s
Research & Development April 20, 2026 UCB to purchase Neurona and NRTX-1001 for $1.15bn By Salong Debbarma The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. Subject to customary conditions and anti-trust clearance, the transaction is